Oncolab S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research program at Oncolab S.R.L. includes studies that address cardiovascular complications linked to cancer treatment, such as cancer-associated thrombosis and drug‑induced platelet disorders.
- Prevention of thrombotic events in patients receiving chemotherapy
- Management of chemotherapy‑induced thrombocytopenia
- Evaluation of cardiovascular safety of novel immunotherapies
These investigations aim to improve patient safety by testing new preventive strategies and assessing the heart‑related side effects of emerging cancer drugs.
Female Urogenital Diseases and Pregnancy Complications
Clinical trials focus on malignancies that affect women, notably ovarian cancer and hormone‑responsive breast cancer, with an emphasis on adjuvant therapies and symptom relief.
- Hormone‑based treatments for early‑stage breast cancer
- Targeted agents for ovarian cancer after surgery
- Management of vasomotor symptoms during endocrine therapy
The goal is to enhance disease‑free survival and quality of life for women undergoing cancer treatment.
Hemic and Lymphatic Diseases
The site conducts research on blood‑related cancers and immune‑system disorders, exploring innovative approaches for conditions such as leukemia and lymphoma.
- Immunotherapy combinations for relapsed hematologic malignancies
- Novel agents targeting specific genetic mutations in blood cancers
- Safety profiling of new biologics in lymphoid diseases
These studies seek to expand treatment options and improve long‑term outcomes for patients with hematologic cancers.
Neoplasms
Oncology remains the core of Oncolab’s activity, with trials covering a broad spectrum of solid tumors, including Non‑Small Cell Lung Cancer, melanoma, and head and neck squamous cell carcinoma.
- Targeted therapies for KRAS‑mutated lung cancer
- Immune‑checkpoint inhibitor combinations in metastatic melanoma
- Adjuvant treatments to prevent recurrence after tumor resection
- Biomarker‑driven trials assessing PD‑L1 expression
The purpose of these investigations is to evaluate the effectiveness of new drugs, compare them with existing standards, and ultimately extend survival for patients with aggressive cancers.
Nutritional and Metabolic Diseases
Research includes metabolic complications of cancer, such as cancer‑associated cachexia, aiming to find interventions that preserve body weight and functional status.
- Therapeutic agents to counteract muscle wasting
- Nutritional support strategies integrated with chemotherapy
- Evaluation of metabolic biomarkers as trial endpoints
These projects focus on improving patients’ overall health and treatment tolerance by addressing the underlying metabolic disturbances of malignancy.
Respiratory Tract Diseases
A significant portion of the portfolio targets lung‑related malignancies, especially small cell lung cancer and advanced Non‑Small Cell Lung Cancer, exploring novel drug combinations and sequencing strategies.
- Sequential use of targeted agents with immunotherapy
- Combination chemotherapy regimens for relapsed small cell lung cancer
- Trials assessing the impact of PD‑L1 status on treatment response
- Studies on maintenance therapy after chemoradiation
The overarching aim is to identify more effective treatment pathways that increase survival and reduce disease progression in patients with respiratory cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1AstraZeneca AB2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oncolab S.R.L.
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2024-02-16 | 2025-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.